Advances in Targeted Therapy of Cholangiocarcinoma

Overview

Journal Ann Med

Publisher Informa Healthcare

Specialty General Medicine

Date 2024 Feb 15

PMID 38359439

Authors

Yuhang Li

Jianfeng Yu

Yujing Zhang

Chuang Peng

Yinghui Song

Sulai Liu

Affiliations

Soon will be listed here.

Abstract

Cholangiocarcinoma (CCA) is a malignant tumor originating in the bile duct and its branching epithelium. Due to its high heterogeneity, there are no specific clinical indications at the early stage, the diagnosis is often in advanced CCA. With surgical resection, the 5-year postoperative survival rate (long-term survival rate) is very poor. The regimen of gemcitabine combined with platinum has been used as the first-line chemotherapy for advanced patients. In recent years, targeted therapy for a variety of malignant tumors has made great progress, showing good efficacy and safety in advanced CCA. However, the current targeted therapy of CCA still has many challenges, such as adverse reactions, drug resistance, and individual differences. Therefore, the researches need to further explore the targeted therapy mechanism of CCA malignancies in depth, develop more effective and safe drugs, and accurately formulate plans based on patient characteristics to further improve patient prognosis in the future. This article reviews the recent progress of targeted therapy for CCA, aiming to provide a strategy for the research and clinical work of targeted therapy for CCA.

Citing Articles

Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance.

Suri C, Pande B, Suhasini Sahithi L, Swarnkar S, Khelkar T, Verma H Cancer Drug Resist. 2025; 8:7.

PMID: 40051496 PMC: 11883236. DOI: 10.20517/cdr.2024.164.

Significant Response to Palbociclib Plus Lenvatinib as Second-line Treatment for CDKN2A/2B Deletion Intrahepatic Cholangiocarcinoma: A Case Report.

Liu K, Huang Z, Zhao L, Zhao H J Clin Transl Hepatol. 2025; 13(2):169-172.

PMID: 39917465 PMC: 11797823. DOI: 10.14218/JCTH.2024.00404.

Role of miRNA‑145‑5p in cancer (Review).

Chen Z, Qin Y Oncol Rep. 2025; 53(3).

PMID: 39886965 PMC: 11800069. DOI: 10.3892/or.2025.8872.

New Relevant Evidence in Cholangiocarcinoma Biology and Characterization.

Porro N, Spinola-Lasso E, Pastore M, Caligiuri A, Di Tommaso L, Marra F Cancers (Basel). 2025; 16(24.

PMID: 39766138 PMC: 11674836. DOI: 10.3390/cancers16244239.

ADAMDEC1 promotes the malignant progression of cholangiocarcinoma by regulating NF-κB signaling pathway.

Zhou S, Yang Y, Qi F, Sun W, Zhang D, Lu Z Sci Rep. 2025; 15(1):817.

PMID: 39755752 PMC: 11700112. DOI: 10.1038/s41598-025-85241-6.

References

Salati M, Caputo F, Baldessari C, Carotenuto P, Messina M, Caramaschi S . The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting. Cancer Manag Res. 2021; 13:7747-7757. PMC: 8517413. DOI: 10.2147/CMAR.S330710. View

Ornitz D, Itoh N . The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015; 4(3):215-66. PMC: 4393358. DOI: 10.1002/wdev.176. View

Jiang Y, Liu Y, Xiao Y, Hu X, Jiang L, Zuo W . Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res. 2020; 31(2):178-186. PMC: 8027015. DOI: 10.1038/s41422-020-0375-9. View

Montal R, Sia D, Montironi C, Leow W, Esteban-Fabro R, Pinyol R . Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol. 2020; 73(2):315-327. PMC: 8418904. DOI: 10.1016/j.jhep.2020.03.008. View

Vogel A, Bridgewater J, Edeline J, Kelley R, Klumpen H, Malka D . Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 34(2):127-140. DOI: 10.1016/j.annonc.2022.10.506. View

Yang H, Ye D, Guan K, Xiong Y . IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res. 2012; 18(20):5562-71. PMC: 3897211. DOI: 10.1158/1078-0432.CCR-12-1773. View

Jiao Y, Pawlik T, Anders R, Selaru F, Streppel M, Lucas D . Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013; 45(12):1470-1473. PMC: 4013720. DOI: 10.1038/ng.2813. View

Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley R, Wang K . Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016; 122(24):3838-3847. DOI: 10.1002/cncr.30254. View

Zhu A, Meyerhardt J, Blaszkowsky L, Kambadakone A, Muzikansky A, Zheng H . Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2009; 11(1):48-54. DOI: 10.1016/S1470-2045(09)70333-X. View

10.

Chen C, Jiang J, Fang M, Zhou L, Chen Y, Zhou J . MicroRNA-129-2-3p directly targets Wip1 to suppress the proliferation and invasion of intrahepatic cholangiocarcinoma. J Cancer. 2020; 11(11):3216-3224. PMC: 7097937. DOI: 10.7150/jca.41492. View

11.

Drilon A . TRK inhibitors in TRK fusion-positive cancers. Ann Oncol. 2020; 30 Suppl 8:viii23-viii30. DOI: 10.1093/annonc/mdz282. View

12.

Massironi S, Pilla L, Elvevi A, Longarini R, Rossi R, Bidoli P . New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. Cells. 2020; 9(3). PMC: 7140695. DOI: 10.3390/cells9030688. View

13.

Taylor M, Schmidt E, Dutcus C, Pinheiro E, Funahashi Y, Lubiniecki G . The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol. 2020; 17(6):637-648. DOI: 10.2217/fon-2020-0937. View

14.

Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M . Genomic spectra of biliary tract cancer. Nat Genet. 2015; 47(9):1003-10. DOI: 10.1038/ng.3375. View

15.

Abou-Alfa G, Macarulla T, Javle M, Kelley R, Lubner S, Adeva J . Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(6):796-807. PMC: 7523268. DOI: 10.1016/S1470-2045(20)30157-1. View

16.

Drilon A, Siena S, Ou S, Patel M, Ahn M, Lee J . Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017; 7(4):400-409. PMC: 5380583. DOI: 10.1158/2159-8290.CD-16-1237. View

17.

Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K . Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010; 11(12):1142-8. DOI: 10.1016/S1470-2045(10)70247-3. View

18.

Tsukada Y, Fang J, Erdjument-Bromage H, Warren M, Borchers C, Tempst P . Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2005; 439(7078):811-6. DOI: 10.1038/nature04433. View

19.

Llovet J, Montal R, Sia D, Finn R . Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018; 15(10):599-616. DOI: 10.1038/s41571-018-0073-4. View

20.

Krook M, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey K . Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. Mol Cancer Ther. 2020; 19(3):847-857. PMC: 7359896. DOI: 10.1158/1535-7163.MCT-19-0631. View